A Multicentre, Randomised, Open-Label, Parallel-Group, Phase IIIb Study to Assess the Potential for Tezepelumab-treated Patients with Severe Asthma to Reduce Background Therapy While Sustaining Asthma Control and Clinical Remission (ARRIVAL)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512113-41-00

Acronym

D5180C00047

Enrollment

152

Registered

2024-10-28

Start date

2024-11-20

Completion date

Unknown

Last updated

2025-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Asthma

Brief summary

Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase (Week 56) to either: Outside of the US: • Medium-dose maintenance and reliever therapy, or • Low-dose maintenance and reliever therapy, or • SYMBICORT® anti-inflammatory reliever only

Interventions

DRUGTezspire 210 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase (Week 56) to either: Outside of the US: • Medium-dose maintenance and reliever therapy, or • Low-dose maintenance and reliever therapy, or • SYMBICORT® anti-inflammatory reliever only	—

Countries

Belgium, Bulgaria, Denmark, France, Germany, Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026